Patents by Inventor Donald Copertino
Donald Copertino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9410185Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.Type: GrantFiled: March 20, 2014Date of Patent: August 9, 2016Assignee: Becton, Dickinson and CompanyInventors: Michael Lizzi, Donald Copertino
-
Patent number: 9267167Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.Type: GrantFiled: June 24, 2005Date of Patent: February 23, 2016Assignee: Becton, Dickinson and CompanyInventors: Michael Justin Lizzi, Donald Copertino
-
Publication number: 20140205996Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.Type: ApplicationFiled: March 20, 2014Publication date: July 24, 2014Applicant: Becton, Dickinson and CompanyInventors: Michael Lizzi, Donald Copertino
-
Publication number: 20100286380Abstract: The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.Type: ApplicationFiled: May 12, 2010Publication date: November 11, 2010Applicant: BECTON, DICKINSON AND COMPANYInventors: Matthew P. Collis, Donald Copertino, Karen Eckert, Thomas Fort
-
Patent number: 7645573Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms.Type: GrantFiled: November 12, 2003Date of Patent: January 12, 2010Assignee: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Jr., Richard L. Moore, Michael L. Towns, Nicholas Bachur, Jr., Robert W. Rosenstein, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
-
Patent number: 7645613Abstract: Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.Type: GrantFiled: December 28, 2006Date of Patent: January 12, 2010Assignee: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Jr., Richard L. Moore, Michael L. Towns, Gary Siuzdak, Elizabeth J. Want, Zhouxin Shen, Nicholas Bachur, Jr., Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
-
Patent number: 7632685Abstract: Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.Type: GrantFiled: December 28, 2006Date of Patent: December 15, 2009Assignee: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Jr., Richard L. Moore, Michael L. Towns, Nicholas Bachur, Jr., Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice, Gary Siuzdak, Elizabeth Want, Zhouxin Shen
-
Publication number: 20080138832Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis.Type: ApplicationFiled: September 25, 2007Publication date: June 12, 2008Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
-
Publication number: 20080050829Abstract: Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.Type: ApplicationFiled: December 28, 2006Publication date: February 28, 2008Inventors: Richard Ivey, Thomas Gentle, Richard Moore, Michael Towns, Nicholas Bachur, Robert Rosenstein, James Nadeau, Paul Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice, Gary Siuzdak, Elizabeth Want, Zhouxin Shen
-
Publication number: 20070184512Abstract: Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.Type: ApplicationFiled: December 28, 2006Publication date: August 9, 2007Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice, Gary Siuzdak, Elizabeth Want, Zhouxin Shen
-
Publication number: 20050287682Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.Type: ApplicationFiled: June 24, 2005Publication date: December 29, 2005Inventors: Michael Lizzi, Donald Copertino
-
Publication number: 20040157242Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms.Type: ApplicationFiled: November 12, 2003Publication date: August 12, 2004Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice, Gary Siuzdak, Elizabeth Want, Zhouxin Shen
-
Publication number: 20040106142Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms.Type: ApplicationFiled: November 12, 2003Publication date: June 3, 2004Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
-
Publication number: 20040096917Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis.Type: ApplicationFiled: November 12, 2003Publication date: May 20, 2004Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
-
Publication number: 20040097460Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis.Type: ApplicationFiled: November 12, 2003Publication date: May 20, 2004Applicant: Becton, Dickinson and CompanyInventors: Richard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice